Johnson & Johnson's Fiscal Year is From January To December - All Figures are in USD, Billions.
The item "Net-Income-Applicable-To-Common-Shares" stands at 25.12 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025, the highest value since 09/30/2024.
Johnson & Johnson's third quarter result of 5.15 Billion USD for the item "Net Income Applicable To Common Shares" represents a decrease of -6.95 percent compared to it's second quarter result.
Also, Johnson & Johnson's third quarter result of 5.15 Billion USD for the item "Net Income Applicable To Common Shares" represents an increase of 91.24 percent compared to it's third quarter result of last year.
Looking again at the trailing twelve months series (TTM), Johnson & Johnson's third quarter result of 25.12 Billion USD for the item "Net Income Applicable To Common Shares" represents an increase of 10.85 percent compared to it's second quarter result.
Regarding the One-Year-Change of the series, the current value constitutes an increase of 71.06 percent compared to the value the year prior.
The 1 year change in percent is 71.06.
The 3 year change in percent is 31.12.
The 5 year change in percent is 47.88.
The 10 year change in percent is 70.70.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Net Income Applicable To Common Shares | 905,699,262,464.00 |
![]() | AbbVie Inc - Net Income Applicable To Common Shares | 399,570,305,024.00 |
![]() | Roche Holding AG - Net Income Applicable To Common Shares | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Net Income Applicable To Common Shares | 280,205,508,085.11 |
![]() | Novartis AG - Net Income Applicable To Common Shares | 255,096,620,580.91 |